Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
69 hedge funds and large institutions have $154M invested in Syros Pharmaceuticals, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 17 closing their positions.
79% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 14
1% more funds holding
Funds holding: 68 → 69 (+1)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
31% less capital invested
Capital invested by funds: $224M → $154M (-$69.9M)
90% less call options, than puts
Call options by funds: $28K | Put options by funds: $267K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$9.4M |
| 2 |
JP Morgan Chase
New York
|
+$2.72M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$1.21M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$437K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$394K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.67M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.53M |
| 3 |
Renaissance Technologies
New York
|
-$1.06M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$975K |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$807K |
SYRS Hedge Fund Activity: Q4 2017 in Review
69 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q4 2017, worth a combined $154M — down 31% from $224M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SYRS positions and 17 closed out — a net gain of 1 holder — while 25 added to existing stakes and 14 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $9.4M. The largest seller was Millennium Management, exiting entirely with an estimated $1.67M sold.
- 69 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q4 2017, up from 68 in Q3 2017.
- Funds reported $154M of Syros Pharmaceuticals, Inc. Common Stock stock for Q4 2017, down 31% quarter-over-quarter.
- 18 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q4 2017 and 17 closed out, a net change of +1 holder.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q4 2017 was ARK Investment Management, an estimated $9.4M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q4 2017 was Millennium Management, an estimated $1.67M sold.
Based on aggregated 13F filings for Q4 2017.